#The News
Rockwell Medical, Inc. (Nasdaq: RMTI) announced its participation in ASN Kidney Week 2025, set to take place from November 6-9 at the George R. Brown Convention Center in Houston, Texas. The company will showcase its hemodialysis concentrates portfolio at Booth #316.
Among the products featured are:
CitraPure® Citric Acid Concentrate: A citric acid-based, 100% acetate-free liquid concentrate available in various packaging.
Dri-Sate® Acid Concentrate: An acetic acid-based dry powder for on-site mixing, producing 25 gallons of liquid concentrate per case.
RenalPure® Acid Concentrate: Available in both liquid and dry forms, designed for hemodialysis.
SteriLyte® Bicarbonate Concentrate: A liquid form packaged for acute care settings.
Bicarbonate Cartridge: A single-use cartridge approved for hemodialysis systems, available in two sizes.
Dry Acid Concentrate Mixer: Exclusively designed for Dri-Sate and CitraPure products to enable efficient on-site mixing.
Cleaning supplies: Essential accessories for dialysis providers.
More details about Rockwell's products can be found on its website.
#Market Impact
Rockwell Medical's participation in ASN Kidney Week enhances its visibility and could lead to increased interest in its hemodialysis products among healthcare providers. Market reactions to the event may affect stock performance.
#What’s Next
Investors should monitor updates from Rockwell Medical following ASN Kidney Week for potential new partnerships or product developments.
#Investor Takeaway
Rockwell's exhibition at ASN Kidney Week highlights its commitment to the hemodialysis market and may influence investor sentiment.